Physician profile
Mark E Kalina
NPI 1275638801
$3,767.20
in general payments reported to CMS, 2019-2025
40 companies · $915 in 2025
The $915 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.02 · 2021: $736 · 2022: $554 · 2023: $742 · 2024: $803 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $718.05 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $637.20 | 2021-2025 | |
| Pfizer INC. | $218.50 | 2021-2024 | |
| Novo Nordisk INC | $198.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $160.11 | 2021-2025 | Nucala, Arexvy, Shingrix |
| Lilly USA, LLC | $157.78 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $131.20 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $121.84 | 2024 | |
| Phadia US INC. | $110.19 | 2025 | Immunocap |
| Gilead Sciences, INC. | $99.99 | 2024-2025 | |
| Amgen INC. | $91.05 | 2021-2022 | |
| Hologic Sales and Service, LLC | $89.46 | 2024-2025 | Aptima |
| Idorsia Pharmaceuticals US INC | $83.64 | 2022-2024 | Quviviq |
| Abbott Laboratories | $67.08 | 2021-2025 | Freestyle Libre 3, Octrode |
| Sanofi-Aventis U.S. LLC | $57.46 | 2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kalina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.